SABCS Marks 40 Years

Kent Osborne, MD, a codirector of SABCS, wrote a guest post for Cancer Research Catalyst in 2015 that details the symposium’s growth. We’re happy to present it again. Check back with Cancer Research Catalyst frequently for updates from SABCS, which will take place Dec. 5-9.

Read More

Vemurafenib Becomes First FDA-approved Treatment for a Rare Type of Blood Cancer

Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults who have a rare type of blood cancer called Erdheim-Chester disease. Vemurafenib targets mutant forms of the protein BRAF, and it has been approved for treating those patients whose Erdheim-Chester disease harbors the BRAF V600 mutation.

Read More

How Does Lung Cancer Evade the Immune System?

Much has been written, including on this blog, about the rapidly expanding use of immunotherapy to treat an increasing array of cancer types, including lung cancer. The development of these new treatments, which harness a patient’s immune system to fight cancer, is built upon many years of basic research in the fields of immunology and cancer biology.

Read More

Honoring the Life of an Advocate

In the fall issue, Cancer Today had the honor of highlighting two women whose cancer diagnoses led them to form a powerful partnership. AnneMarie Ciccarella and Lori Marx-Rubiner met each other after attending a weekly Twitter chat under the social media hashtag #BCSM (for Breast Cancer Social Media). They formed an unbreakable bond that challenged them both—and ultimately affected many researchers.

Read More

Learning From the Immune System of Long-term Pancreatic Cancer Survivors

Pancreatic cancer is a deadly disease with a five-year survival rate of a mere 8.2 percent, according to statistics from the SEER database. Unfortunately, the last 30 years has not seen any significant improvement in survival for patients with this disease. Pancreatic cancer is projected to become the second leading cause of deaths due to cancer in the United States by 2030.

Read More

Advances in Tobacco Control

Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung Cancer Awareness Month, is a good time to highlight new advances in tobacco control, such as the legislation that came into effect Nov. 1, 2017, in New Jersey that raises the minimum age of legal access to tobacco products to 21.

Read More